| (Values in U.S. Thousands) | Mar, 2020 | Dec, 2019 | Sep, 2019 | Jun, 2019 | Mar, 2019 |
| Sales | 1,760 | 1,690 | 3,340 | 1,070 | 1,270 |
| Sales Growth | +4.14% | -49.40% | +212.15% | -15.75% | -70.33% |
| Net Income | -12,120 | -11,370 | -16,300 | -22,920 | -19,490 |
| Net Income Growth | -6.60% | +30.25% | +28.88% | -17.60% | +9.26% |
Tetraphase Pharmaceu (TTPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.
Fiscal Year End Date: 12/31